Literature DB >> 27308434

Eat this, not that! How selective autophagy helps cancer cells survive.

Robin Mathew1, Eileen White2.   

Abstract

Autophagy degrades the cellular proteome to promote survival, but the underlying mechanism and substrates of consequence are poorly understood. We found that autophagy selectively remodels the proteome in cancer cells by eliminating proinflammatory signaling proteins. Autophagy ablation causes aberrant accumulation of these proteins that primes cancer cells for interferon-dependent cell death, explaining how autophagy suppresses inflammation and promotes tumor maintenance.

Entities:  

Keywords:  autophagy; biomarkers; immuno-oncology; innate immunity; interferon

Year:  2015        PMID: 27308434      PMCID: PMC4904891          DOI: 10.4161/23723556.2014.975638

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN: 2372-3556


  11 in total

1.  Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisions.

Authors:  Sarah E Henrickson; Mario Perro; Scott M Loughhead; Balimkiz Senman; Susanne Stutte; Michael Quigley; Gabriela Alexe; Matteo Iannacone; Michael P Flynn; Shaida Omid; Jonathan L Jesneck; Sabrina Imam; Thorsten R Mempel; Irina B Mazo; W Nicholas Haining; Ulrich H von Andrian
Journal:  Immunity       Date:  2013-09-19       Impact factor: 31.745

2.  Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression.

Authors:  Giulia Escobar; Davide Moi; Anna Ranghetti; Pinar Ozkal-Baydin; Mario Leonardo Squadrito; Anna Kajaste-Rudnitski; Attilio Bondanza; Bernhard Gentner; Michele De Palma; Roberta Mazzieri; Luigi Naldini
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

3.  Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis.

Authors:  Jessie Yanxiang Guo; Gizem Karsli-Uzunbas; Robin Mathew; Seena C Aisner; Jurre J Kamphorst; Anne M Strohecker; Guanghua Chen; Sandy Price; Wenyun Lu; Xin Teng; Eric Snyder; Urmila Santanam; Robert S Dipaola; Tyler Jacks; Joshua D Rabinowitz; Eileen White
Journal:  Genes Dev       Date:  2013-07-01       Impact factor: 11.361

4.  Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis.

Authors:  Giovanna Schiavoni; Antonella Sistigu; Mara Valentini; Fabrizio Mattei; Paola Sestili; Francesca Spadaro; Massimo Sanchez; Silvia Lorenzi; Maria Teresa D'Urso; Filippo Belardelli; Lucia Gabriele; Enrico Proietti; Laura Bracci
Journal:  Cancer Res       Date:  2010-12-13       Impact factor: 12.701

5.  Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.

Authors:  Juan Dubrot; Asis Palazón; Carlos Alfaro; Arantza Azpilikueta; María Carmen Ochoa; Ana Rouzaut; Iván Martinez-Forero; Alvaro Teijeira; Pedro Berraondo; Agnes Le Bon; Sandra Hervás-Stubbs; Ignacio Melero
Journal:  Int J Cancer       Date:  2011-01-01       Impact factor: 7.396

6.  Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity.

Authors:  Robin Mathew; Sinan Khor; Sean R Hackett; Joshua D Rabinowitz; David H Perlman; Eileen White
Journal:  Mol Cell       Date:  2014-08-28       Impact factor: 17.970

Review 7.  Exploiting the bad eating habits of Ras-driven cancers.

Authors:  Eileen White
Journal:  Genes Dev       Date:  2013-10-01       Impact factor: 11.361

Review 8.  Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.

Authors:  Giovanna Schiavoni; Fabrizio Mattei; Lucia Gabriele
Journal:  Front Immunol       Date:  2013-12-25       Impact factor: 7.561

9.  IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Authors:  Richard Metz; Sonja Rust; James B Duhadaway; Mario R Mautino; David H Munn; Nicholas N Vahanian; Charles J Link; George C Prendergast
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

10.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Authors:  Rikke B Holmgaard; Dmitriy Zamarin; David H Munn; Jedd D Wolchok; James P Allison
Journal:  J Exp Med       Date:  2013-06-10       Impact factor: 14.307

View more
  2 in total

1.  GRP94 Is Involved in the Lipid Phenotype of Brain Metastatic Cells.

Authors:  Naiara Santana-Codina; Anna Marcé-Grau; Laia Muixí; Claudia Nieva; Mónica Marro; David Sebastián; Juan Pablo Muñoz; Antonio Zorzano; Angels Sierra
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

Review 2.  Functions and Implications of Autophagy in Colon Cancer.

Authors:  Samantha N Devenport; Yatrik M Shah
Journal:  Cells       Date:  2019-10-30       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.